#LCSM Transcript

Healthcare social media transcript of the #LCSM hashtag.
().
See #LCSM Influencers/Analytics.

ProfileTweet
Brendon Stiles @BrendonStilesMD
Welcome everyone! You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Welcome everyone! You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Welcome everyone! You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Henning Willers, MD, FASTRO @HenningWillers
RT @BrendonStilesMD: Hi everyone. Starting soon. Please join #lcsm community and @lcsmchat to discuss #wclc19 from @iaslc! Starting in j…
Jean Parks @geekbabe
RT @BrendonStilesMD: Hi everyone. Starting soon. Please join #lcsm community and @lcsmchat to discuss #wclc19 from @iaslc! Starting in j…
Jill Feldman @jillfeldman4
Hi it's Jill from Chicago. Looking forward to your recap of #WCLC19 @BrendonStilesMD #LCSM
Brendon Stiles @BrendonStilesMD
To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twi…
Brendon Stiles @BrendonStilesMD
More info at https://t.co/Lx9qF406C9 #lcsm
Bob Steele @steele_bob
Good evening folks. Bob here in Greensboro, NC. Looking 4ward to hearing the news from Spain. #lcsm
Brendon Stiles @BrendonStilesMD
@jillfeldman4 Looking forward to hearing your thoughts! #lcsm
Janet Freeman-Daily @JFreemanDaily
Good evening all! Janet Freeman-Daily in Seattle. Looking forward to tonight's chat about #WCLC19 wrap-up! #LCSM
Brendon Stiles @BrendonStilesMD
@GinaHollenbeck Hi Gina! #lcsm
Lung Cancer Research Foundation @lcrf_org
Excited about tonight’s #LCSM chat and catching up after this year's #wclc2019 with @BrendonStilesMD. Join us!
@LungCancerFaces
Deana here in muggy Los Angeles. I’ll be tweeting from the @lcsmchat account tonight. #lcsm
Jean Parks @geekbabe
Hi everyone stage IV almost 5 yrs, treated at @MGHCancerCenter #LCSM
Brendon Stiles @BrendonStilesMD
We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm
Tim Kruser @TimothyKruserMD
Tim Kruser here. Looking forward to learning as had to miss WCLC19 given it was back-to-back with #ASTRO19 :( #lcsm
Brendon Stiles @BrendonStilesMD
@TimothyKruserMD Always love your input! #lcsm
#LCSM Chat @lcsmchat
@steele_bob Evening, Bob! #lcsm
Lung Cancer Sux @LungCancerSux
@BrendonStilesMD @jillfeldman4 Hi! Glorianne in CT signing on! Great topic! #LCSM
Peggy Dennis @peggyddennis
Peggy Dennis joining from Denver. Looking forward to the update. #lcsm
Brendon Stiles @BrendonStilesMD
I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and @IASLC member. #lcsm
Brendon Stiles @BrendonStilesMD
I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife works for @ppdCRO. These don’t affect opinions expressed tonight. #lcsm
Brendon Stiles @BrendonStilesMD
@LungCancerSux @jillfeldman4 So glad you are here! #lcsm
Janet Freeman-Daily @JFreemanDaily
@GinaHollenbeck @BrendonStilesMD Hi Gina! Remember to include #LCSM in all your tweets so they'll appear in the Chat.
#LCSM Chat @lcsmchat
@LungCancerSux @BrendonStilesMD @jillfeldman4 Hi Jill and Glorianne! #lcsm
KC Dill @kasedill
Hello from Houston, we are high and dry in the suburbs, lots of rain here.. #LCSM
Brendon Stiles @BrendonStilesMD
[REDACTED USER] Hi Jill. A true STAR! #lcsm
Henning Willers, MD, FASTRO @HenningWillers
Hi all, @henningwillers here, also fresh back from ASTRO19 but wasn't at World Lung #lcsm
Gina Hollenbeck @GinaHollenbeck
Hi! Gina here. Stage IV, ALK Positive- President of ALK Positivw a Patient lead group of 1800+ patients and caregivers #lcsm
Brendon Stiles @BrendonStilesMD
In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV
Jean Parks @geekbabe
RT @BrendonStilesMD: I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife works for…
#LCSM Chat @lcsmchat
@BrendonStilesMD @GinaHollenbeck Welcome, Gina! Remember to include #lcsm in all your tweets.
Deb 🌅 @debsmithbeach
Deb here, from NH. 8 yrs post dx, on Tagrisso almost 6 yrs, EGFR/T790. #lcsm
#LCSM Chat @lcsmchat
@geekbabe @MGHCancerCenter Hey, Jean! #lcsm
Brendon Stiles @BrendonStilesMD
@HenningWillers @HenningWillers Glad you made it! #lcsm Sorry to miss ASTRO!
#LCSM Chat @lcsmchat
@TimothyKruserMD Welcome! #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV
#LCSM Chat @lcsmchat
@peggyddennis Hi Peggy! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and @IASLC member. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife works for…
#LCSM Chat @lcsmchat
[REDACTED USER] Hey Jill! #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV
Brendon Stiles @BrendonStilesMD
#WCLC19 is a showcase for all of the latest news and advances in lung cancer #lcsm
#LCSM Chat @lcsmchat
@kasedill Welcome! #lcsm
Gina @EAustin1969
Gina and I’m actually here. Can’t wait to hear all the new stuff #LCSM
Brendon Stiles @BrendonStilesMD
We will get started soon. First, a few reminders… #lcsm
#LCSM Chat @lcsmchat
@HenningWillers Welcome! #lcsm
Brendon Stiles @BrendonStilesMD
Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm
#LCSM Chat @lcsmchat
@GinaHollenbeck Hey Gina! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV
Brendon Stiles @BrendonStilesMD
If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience. #lcsm
#LCSM Chat @lcsmchat
@debsmithbeach Hi Deb! #lcsm
Brendon Stiles @BrendonStilesMD
I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm
#LCSM Chat @lcsmchat
@EAustin1969 Hello Gina! #lcsm
Brendon Stiles @BrendonStilesMD
We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. Great group already! #lcsm
NCI Cancer Stats @NCICancerStats
The overall trends for new cases and deaths of lung and bronchial cancer have steadily declined since 1995. Learn more about this cancer from our stat fact sheet: https://t.co/BVqvN4e1pm #LCSM https://t.co/qFHrSzI6BL
Brendon Stiles @BrendonStilesMD
[REDACTED USER] Thanks for joining! #lcsm
Brendon Stiles @BrendonStilesMD
@EAustin1969 Glad you made it! #lcsm
#LCSM Chat @lcsmchat
[REDACTED USER] Welcome, Charis! #lcsm
Brendon Stiles @BrendonStilesMD
T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm
yetAnotherName @glostaMAssachu
Hi, Betsy here, listening intently 😊 #LCSM
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm
#LCSM Chat @lcsmchat
@wildwestannie Hi Betsy! #lcsm
Brendon Stiles @BrendonStilesMD
T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm
Brendon Stiles @BrendonStilesMD
T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currently used. https://t.co/vWMM0ySB3y #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm
@puterimaya6
https://t.co/vKz0sMg9MI , #geekyweather, #gobirds, #infinite, #mugclub, #prichan, #nstemi, #pegged, #losamoresstyle, #6o, #marijuana, #lcsm, #mytcisbetterbecause, #clinicadelgado, #jumatberkah, #wjsn,
Brendon Stiles @BrendonStilesMD
T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl…
Janet Freeman-Daily @JFreemanDaily
Lots of plenary presentations about #lungcancer #screening at #WCLC19. Here's one take home message. #LCSM
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl…
Brendon Stiles @BrendonStilesMD
Never smokers take note! #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm
Jill Feldman @jillfeldman4
T1 the presidential symposium featured abstracts on strategies to improve efficiency of screening. The one on blood test to identify tumor markers is huge - fingers crossed! #LCSM
Henning Willers, MD, FASTRO @HenningWillers
RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
"...screening with low-dose CT saves lives by reducing lung cancer mortality by at least 20%..." #lcsm
#LCSM Chat @lcsmchat
@shelly_et Hey Shelly! Awesome haircut at #WCLC19 #lcsm
Brendon Stiles @BrendonStilesMD
T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5J #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm
Brendon Stiles @BrendonStilesMD
@shelly_et Hi Shelly! #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Lots of plenary presentations about #lungcancer #screening at #WCLC19. Here's one take home message. #LCSM https://t.co…
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5…
colleen ziegler @ZieglerColleen
#lcsm a few minutes late...Colleen from Rochester joining
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: "...screening with low-dose CT saves lives by reducing lung cancer mortality by at least 20%..." #lcsm https://t.co/B7RsT…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5…
Janet Freeman-Daily @JFreemanDaily
Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19
Jean Parks @geekbabe
RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5…
Brendon Stiles @BrendonStilesMD
T1. This study was also important because it included a high rate of low income patients and demonstrated high adherence rates, even in this high risk group. #lcsm https://t.co/Jud9FF3ULi
Bob Steele @steele_bob
RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM
#LCSM Chat @lcsmchat
@ZieglerColleen Hi Colleen! #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
"...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere…
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: "...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm https://t.co/n0u7N…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM
Brendon Stiles @BrendonStilesMD
T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to improve detection rates and to guide screening intervals. #lcsm https://t.co/YiqIvDo6FP
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere…
Brendon Stiles @BrendonStilesMD
RT @TimAllenMDJD: "...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm https://t.co/n0u7N…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp…
Lung Cancer Research Foundation @lcrf_org
Lung cancer screening: such an important topic with so much potential for impact. It is great to see continued progress on this front. #lcsm
Brendon Stiles @BrendonStilesMD
T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm
Janet Freeman-Daily @JFreemanDaily
More from a #WCLC19 plenary about #lungcancer #screening. #lcsm
#LCSM Chat @lcsmchat
I’m partial to purple (Deana) #lcsm
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5…
KC Dill @kasedill
@BrendonStilesMD T1 Sounds more cost effective for the patient..
Bob Steele @steele_bob
RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc
Brendon Stiles @BrendonStilesMD
T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc
Jean Parks @geekbabe
@BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM
Brendon Stiles @BrendonStilesMD
[REDACTED USER] Totally agree. Scottish study went a long way towards this. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm
Brendon Stiles @BrendonStilesMD
RT @geekbabe: @BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM
Bob Steele @steele_bob
RT @geekbabe: @BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM
KC Dill @kasedill
RT @BrendonStilesMD: T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl…
Henning Willers, MD, FASTRO @HenningWillers
@BrendonStilesMD T1 what does personal prevention mean?
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm
Lung Cancer Research Foundation @lcrf_org
RT @geekbabe: @BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM
OurWarOnCancer @OurWarOnCancer
RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp…
Brendon Stiles @BrendonStilesMD
@HenningWillers That screening need and interval should be defined by individual risks. Suppose not really prevention... #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Personalized Prevention: the new personalized medicine #lcsm
OurWarOnCancer @OurWarOnCancer
RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere…
Brendon Stiles @BrendonStilesMD
RT @lcrf_org: Lung cancer screening: such an important topic with so much potential for impact. It is great to see continued progress on th…
Bob Steele @steele_bob
RT @TimAllenMDJD: Personalized Prevention: the new personalized medicine #lcsm https://t.co/0OXR2XgHin
Deb 🌅 @debsmithbeach
@BrendonStilesMD I’m glad to see non smokers considered! #LCSM
Jean Parks @geekbabe
@TimAllenMDJD @BrendonStilesMD P53 would have caught me before I was stage IV #LCSM
Laura Greco @lgreco_ny
Laura here,late. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5…
Bob Steele @steele_bob
RT @BrendonStilesMD: @HenningWillers That screening need and interval should be defined by individual risks. Suppose not really prevention.…
Laura Book @LauraJBook
@BrendonStilesMD Glad they are including nonsmoking criteria for assessing screening risks
KC Dill @kasedill
@lgreco_ny Hi Laura #LCSM
Brendon Stiles @BrendonStilesMD
T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere…
@LungCancerFaces
If you’re just watching, please send a blank tweet with the hashtag #lcsm so we know you’re out there.
Brendon Stiles @BrendonStilesMD
T2 coming soon! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm
Brendon Stiles @BrendonStilesMD
RT @LungCancerFaces: If you’re just watching, please send a blank tweet with the hashtag #lcsm so we know you’re out there.
Tim Kruser @TimothyKruserMD
T1. Hope efforts at better accuracy can erode (good faith) opposition from those like @VPrasadMDMPH--need increase screening rates! #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm
#LCSM Chat @lcsmchat
@lgreco_ny Hey Laura! #lcsm
Brendon Stiles @BrendonStilesMD
T2 will need some oncologists and pathologists! #lcsm
Bob Steele @steele_bob
RT @TimothyKruserMD: T1. Hope efforts at better accuracy can erode (good faith) opposition from those like @VPrasadMDMPH--need increase scr…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @HenningWillers That screening need and interval should be defined by individual risks. Suppose not really prevention.…
OurWarOnCancer @OurWarOnCancer
RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM
Gina Hollenbeck @GinaHollenbeck
@BrendonStilesMD A mobile unit was on display for screening in rural areas. Wish it wasn’t just for smokers. #WCLC2019, #lcsm https://t.co/4L7TemzWnR
Brendon Stiles @BrendonStilesMD
T2. What is important to know about molecular testing? Is universal testing coming? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm
#LCSM Chat @lcsmchat
RT @LungCancerFaces: If you’re just watching, please send a blank tweet with the hashtag #lcsm so we know you’re out there.
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm
Deb 🌅 @debsmithbeach
@BrendonStilesMD T1: What factors are involved for nonsmokers? I’m curious if I would qualify for screening. #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
Hi- Lecia Sequist, med Onc from MGH here trying to catch a few topics while also at a middle school back to school night. #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm
KC Dill @kasedill
RT @BrendonStilesMD: T2 will need some oncologists and pathologists! #lcsm
Brendon Stiles @BrendonStilesMD
T2. Great session on testing for molecular markers at #WCLC19 including talks by @DCarboneMD and @ChristianRolfo #lcsm https://t.co/qMRwz4DQNl
Brendon Stiles @BrendonStilesMD
RT @TimAllenMDJD: You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm https://t.co/WSMN3IK6TU
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @LungCancerFaces: If you’re just watching, please send a blank tweet with the hashtag #lcsm so we know you’re out there.
Brendon Stiles @BrendonStilesMD
@LeciaSequist Always amazing! Thanks for joining! #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
NGS FTW #lcsm
Lung Cancer Research Foundation @lcrf_org
One step closer to the ever elusive "liquid biopsy": RT @BrendonStilesMD: T1. BioMILD article: https://t.co/XlZOf2hhUm #lcsm
Brendon Stiles @BrendonStilesMD
T2. There is remarkable variability in what individual institutions test for. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. What is important to know about molecular testing? Is universal testing coming? #lcsm
@LungCancerFaces
@TimothyKruserMD @VPrasadMDMPH You’re a Doc after my own heart, Tim. #lcsm
Brendon Stiles @BrendonStilesMD
T2. Matthew Smeltzer presented results from @iaslc survey: https://t.co/roNRDeCfkG #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: Hi- Lecia Sequist, med Onc from MGH here trying to catch a few topics while also at a middle school back to school night.…
Janet Freeman-Daily @JFreemanDaily
@LeciaSequist Welcome Lecia! #LCSM
Brendon Stiles @BrendonStilesMD
T2. Top five barriers: cost, quality, access, awareness, and time. We have to break these down systematically. Lives depend upon it. #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Back atcha @LungCancerFaces #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T2. Great session on testing for molecular markers at #WCLC19 including talks by @DCarboneMD and @ChristianRolfo #lcs
Chandan Das @ckdasoncology
RT @KadrinWilfong: @PeerView Live at #ASTRO19: Dr. Kathryn Beal, @PatelOncology , and @BrainTumorDoc share an algorithm for management of n…
Ehsan H. Balagamwala @DrEHBalagamwala
RT @JAMAOnc: Rand ph2 trial of pembro vs stereotactic body radiation therapy (SBRT) to a lesion before pembro for adv NSCLC shows doubling…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2 will need some oncologists and pathologists! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Great session on testing for molecular markers at #WCLC19 including talks by @DCarboneMD and @ChristianRolfo #lcs
Brendon Stiles @BrendonStilesMD
T2. Currently, too many stage IV patients are not tested or have therapy started prior to testing results coming back – especially in developing countries. #lcsm
Laura Greco @lgreco_ny
@kasedill @lgreco_ny #lcsm
#LCSM Chat @lcsmchat
@LeciaSequist Welcome! #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Need evidence-based standardization. #lcsm
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD @DCarboneMD @ChristianRolfo That session went by REALLY fast. I'll have to rewatch it a few times to absorb everything. #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Great session on testing for molecular markers at #WCLC19 including talks by @DCarboneMD and @ChristianRolfo #lcs
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: NGS FTW #lcsm https://t.co/QewB9ywD45
Brendon Stiles @BrendonStilesMD
T2. Older study, but problem still pervasive. #lcsm https://t.co/dSO0BgjaH3
#LCSM Chat @lcsmchat
[REDACTED USER] @LungCancerFaces Welcome, Bill. #lcsm
#LCSM Chat @lcsmchat
RT @lcrf_org: One step closer to the ever elusive "liquid biopsy": RT @BrendonStilesMD: T1. BioMILD article: https://t.co/XlZOf2hhUm #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. There is remarkable variability in what individual institutions test for. #lcsm
Brendon Stiles @BrendonStilesMD
T2. Not testing can sometimes lead to ineffective or even counterproductive treatments. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Matthew Smeltzer presented results from @iaslc survey: https://t.co/roNRDeCfkG #lcsm
yetAnotherName @glostaMAssachu
RT @TimAllenMDJD: You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm https://t.co/WSMN3IK6TU
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Top five barriers: cost, quality, access, awareness, and time. We have to break these down systematically. Liv…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Currently, too many stage IV patients are not tested or have therapy started prior to testing results coming back…
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Need evidence-based standardization. #lcsm https://t.co/tygTMns5jj
Brendon Stiles @BrendonStilesMD
T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV
Brendon Stiles @BrendonStilesMD
T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm
Bob Steele @steele_bob
RT @TimAllenMDJD: Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV https…
Lung Cancer Sux @LungCancerSux
RT @TimAllenMDJD: Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV https…
Bob Steele @steele_bob
RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD My take away from that session: there are many types of biomarker testing, and some work better for certain biomarkers than others. No one test is perfect for all. Might be good to perform both liquid biopsy and tissue biopsy if possible. #LCSM
Brendon Stiles @BrendonStilesMD
T2. In my opinion, it is critical to test all stage IV tumors. Here are good guidelines from @JTOonline and @ChristianRolfo #lcsm https://t.co/PAlpXCfgqR
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
#StandardOfCare #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @lcrf_org: One step closer to the ever elusive "liquid biopsy": RT @BrendonStilesMD: T1. BioMILD article: https://t.co/XlZOf2hhUm #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. There is remarkable variability in what individual institutions test for. #lcsm
@LungCancerFaces
Welcome, Sue! Glad you’re here. If you want to tweet during the chat, remember to include the hashtag #lcsm.
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Matthew Smeltzer presented results from @iaslc survey: https://t.co/roNRDeCfkG #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T2. In my opinion, it is critical to test all stage IV tumors. Here are good guidelines from @JTOonline and @Christi
Brendon Stiles @BrendonStilesMD
T2. Great point by @DCarboneMD that the cost of molecular testing is often less than that of a single PET scan – and often much more impactful! #lcsm https://t.co/iwIlXbgvaf
@LungCancerFaces
#lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Need evidence-based standardization. #lcsm https://t.co/tygTMns5jj
Deb 🌅 @debsmithbeach
RT @JFreemanDaily: @BrendonStilesMD My take away from that session: there are many types of biomarker testing, and some work better for cer…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ
Brendon Stiles @BrendonStilesMD
And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X
Chris Martin @CMPR
#lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @BrendonStilesMD My take away from that session: there are many types of biomarker testing, and some work better for cer…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. In my opinion, it is critical to test all stage IV tumors. Here are good guidelines from @JTOonline and @Christi
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ
Brendon Stiles @BrendonStilesMD
T3 on way! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Great point by @DCarboneMD that the cost of molecular testing is often less than that of a single PET scan – and…
#LCSM Chat @lcsmchat
RT @LungCancerFaces: #lcsm https://t.co/cmH4zKXlNr
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. In my opinion, it is critical to test all stage IV tumors. Here are good guidelines from @JTOonline and @Christi
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X
@jmeberth
Hi #lcsm crew! Hated to miss @IASLC meeting and was hoping to hear @BrendonStilesMD’s take on the best of the best! Nice to see you all...
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
And yet payment for biomarker testing remains problematic! Patients usually don't know this. #lcsm #CBCIV
#LCSM Chat @lcsmchat
@CMPR Welcome, Chris! #lcsm
Brendon Stiles @BrendonStilesMD
T3. What was new at #WCLC19 regarding immunotherapy? #lcsm
KC Dill @kasedill
RT @BrendonStilesMD: And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X
Brendon Stiles @BrendonStilesMD
@jmeberth @IASLC HELLO! Hope all is well! #lcsm
#LCSM Chat @lcsmchat
@jmeberth @IASLC @BrendonStilesMD Thanks for joining! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X
tauromaquiaficionado @taurinaficion
RT @IASLC: Join Latin America’s largest gathering of clinicians, researchers and scientists in the field of #LungCancer and thoracic oncolo…
Dave Bjork @bjork5
@BrendonStilesMD Just joining...sorry I’m late! Dave here from Boston 😊 #LCSM
Drew Moghanaki @DrewMoghanaki
RT @JFreemanDaily: Lots of plenary presentations about #lungcancer #screening at #WCLC19. Here's one take home message. #LCSM https://t.co…
Jean Parks @geekbabe
What’s sad is small hospitals who don’t do much molecular testing #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Still very complicated. #lcsm
Brendon Stiles @BrendonStilesMD
T3. There were several important immunotherapy presentations at #WCLC19 #lcsm
Enlightening Results 💡 @GraceCordovano
RT @JFreemanDaily: @BrendonStilesMD My take away from that session: there are many types of biomarker testing, and some work better for cer…
#LCSM Chat @lcsmchat
@bjork5 @BrendonStilesMD Hey, Dave! You’ve been a busy guy. #lcsm
Brendon Stiles @BrendonStilesMD
@bjork5 Will take you any time! Thanks for joining! #lcsm
#LCSM Chat @lcsmchat
RT @geekbabe: What’s sad is small hospitals who don’t do much molecular testing #LCSM https://t.co/BRBrJLm5up
Brendon Stiles @BrendonStilesMD
[REDACTED USER] Thanks for joining! #lcsm
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Still very complicated. #lcsm https://t.co/vkbjYwOpgp
Brendon Stiles @BrendonStilesMD
T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very challenging cancer to treat. #lcsm
#LCSM Chat @lcsmchat
[REDACTED USER] Hola! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very cha…
Dave Bjork @bjork5
@lcsmchat @BrendonStilesMD Ha! We’re all out there... in this together! #lcsm #clinicaltrials
Jean Parks @geekbabe
RT @BrendonStilesMD: T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very cha…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very cha…
Brendon Stiles @BrendonStilesMD
T3. Still long way to go for small cell lung cancer. Curves still continue down without plateau. #lcsm https://t.co/bYfP0OnJ0K
Brendon Stiles @BrendonStilesMD
T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm
@jmeberth
@BrendonStilesMD Also, lots of variability in timeliness and quality of treatments applied. There should be better incentives to get folks tested and treated based on evidence based guidelines. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Still long way to go for small cell lung cancer. Curves still continue down without plateau. #lcsm https://t.co/…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm
Brendon Stiles @BrendonStilesMD
T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm
Brendon Stiles @BrendonStilesMD
T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effect in major study presented at #WCLC19 https://t.co/VmgMmGX7N6 #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm
Brendon Stiles @BrendonStilesMD
#lcsm
#LCSM Chat @lcsmchat
@CMPR We 💖 IASLC. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. Still long way to go for small cell lung cancer. Curves still continue down without plateau. #lcsm https://t.co/…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very cha…
Brendon Stiles @BrendonStilesMD
T3. Immunotherapy also continues to move into the treatment plan for earlier stage patients w/ some remarkable responses. https://t.co/f16yTGVQsN #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @jmeberth: @BrendonStilesMD Also, lots of variability in timeliness and quality of treatments applied. There should be better incentives…
Jean Parks @geekbabe
RT @BrendonStilesMD: T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm
Bob Steele @steele_bob
RT @TimAllenMDJD: Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm https://t.co/TJgUu6fvst
Brendon Stiles @BrendonStilesMD
@TimAllenMDJD Agree totally. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effec…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effec…
KC Dill @kasedill
RT @BrendonStilesMD: T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effec…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
#Hope #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm https://t.co/TJgUu6fvst
Dave Bjork @bjork5
#PrecisionMedicine #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. Immunotherapy also continues to move into the treatment plan for earlier stage patients w/ some remarkable respon…
Brendon Stiles @BrendonStilesMD
T3. In NADIM with preop immunotherapy, 83% major path response. 91% survival at 18 months in this high risk stage III group! If holds will be new standard of care for IIIA. #lcsm
Jean Parks @geekbabe
RT @LeciaSequist: Hi- Lecia Sequist, med Onc from MGH here trying to catch a few topics while also at a middle school back to school night.…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Jury's still out on TMB. #lcsm
Tim Kruser @TimothyKruserMD
T3. Some questions remain still in ES-SCLC despite Caspian and IM-133 data--but stepping in the right direction. [REDACTED USER] #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @TimothyKruserMD: T3. Some questions remain still in ES-SCLC despite Caspian and IM-133 data--but stepping in the right direction. @DrAl
Brendon Stiles @BrendonStilesMD
T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over 4x with chemo. Is cure possible? https://t.co/85aIzpvHFI #lcsm
Lung Cancer Sux @LungCancerSux
RT @BrendonStilesMD: T3. Immunotherapy also continues to move into the treatment plan for earlier stage patients w/ some remarkable respon…
Matthew Katz, MD 🇺🇸🟦 @subatomicdoc
RT @BrendonStilesMD: T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effec…
Brendon Stiles @BrendonStilesMD
@TimAllenMDJD What do you think Tim? #lcsm
Henning Willers, MD, FASTRO @HenningWillers
T3 what about neoadjuvant IO + chemo? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Jury's still out on TMB. #lcsm https://t.co/fRlldZm2s2
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Solid. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimothyKruserMD: T3. Some questions remain still in ES-SCLC despite Caspian and IM-133 data--but stepping in the right direction. @DrAl
Stephen V Liu, MD @StephenVLiu
T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR #NSCLC identified and 36% never received an EGFR TKI. Survival 21 months with TKI vs 13.3 without. #LCSM https://t.co/zJeL9UtpYe
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over…
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Jury's still out on TMB. #lcsm https://t.co/fRlldZm2s2
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
All kinds of combinations are being studied. It's exploded! #lcsm
#LCSM Chat @lcsmchat
RT @TimothyKruserMD: T3. Some questions remain still in ES-SCLC despite Caspian and IM-133 data--but stepping in the right direction. @DrAl
Brendon Stiles @BrendonStilesMD
@HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose SBRT over chemo any day! Our trial with Durva + 8Gy x 3 was presented at #WCLC19. Encouraging results. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @StephenVLiu: T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: All kinds of combinations are being studied. It's exploded! #lcsm https://t.co/mteduvc17y
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Solid. #lcsm https://t.co/Lp1BzSRoH1
#LCSM Chat @lcsmchat
RT @StephenVLiu: T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR
Laura Greco @lgreco_ny
@HenningWillers It's so interesting... is maybe sequencing everything? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose…
Brendon Stiles @BrendonStilesMD
@TimAllenMDJD Some say it is getting ahead of itself. But I think it is a critical area for stage II/III in particular. Neoadjuvant IO makes much more sense to me than adjuvant! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose…
KC Dill @kasedill
T3 Nivolumab was a game changer for me! #LCSM
Tim Kruser @TimothyKruserMD
RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose…
Brendon Stiles @BrendonStilesMD
T4 just around the corner - new targets! #lcsm
Henning Willers, MD, FASTRO @HenningWillers
@BrendonStilesMD T3 we are with you 👍 #radonc #Sabr #lcsm
Lung Cancer Research Foundation @lcrf_org
@TimAllenMDJD So much work to be done on sorting out the combinations and sequencing of therapy! #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
It may play a useful role when assessed along with other molecular biomarkers. Speculation though. #lcsm #CBCIV
Jean Parks @geekbabe
RT @BrendonStilesMD: T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over…
Brendon Stiles @BrendonStilesMD
@lgreco_ny @HenningWillers I do think sequencing will come to be important for almost everything in lung cancer! #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @lgreco_ny: @HenningWillers It's so interesting... is maybe sequencing everything? #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose…
Matthew Katz, MD 🇺🇸🟦 @subatomicdoc
RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose…
Ryan Lee @ry_c_lee
🎙 Fresh Episode!🎙 LIVE! 🚨 . Paula Gonyea is the Network Director of Radiology for UVM Health Network and she shares a story of gumption from when she was a young parent. Then we talk about healthcare, insurance, and… https://t.co/AHI2bsHyuI
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @StephenVLiu: T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR
Brendon Stiles @BrendonStilesMD
T4. Are there any exciting new targets being investigated in lung cancer? #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T4. Are there any exciting new targets being investigated in lung cancer? #lcsm
#LCSM Chat @lcsmchat
RT @lcrf_org: @TimAllenMDJD So much work to be done on sorting out the combinations and sequencing of therapy! #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
NGS FTW #lcsm
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: It may play a useful role when assessed along with other molecular biomarkers. Speculation though. #lcsm #CBCIV https://t…
Laura Greco @lgreco_ny
Different topic, but I'd love to see greatest hits for #astro19 relating to lc/ brain mets #lcsm @HenningWillers @BrendonStilesMD @lcrf_org
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @lgreco_ny @HenningWillers I do think sequencing will come to be important for almost everything in lung cancer! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Are there any exciting new targets being investigated in lung cancer? #lcsm
KC Dill @kasedill
RT @BrendonStilesMD: T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over…
Gina @EAustin1969
T3: it’s heartening I see so much progress on treatment options , it’s expanded so much in just 5 years #lcsm
Brendon Stiles @BrendonStilesMD
T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm
Jean Parks @geekbabe
@BrendonStilesMD Have been on Opdivo for well over 4 yrs, patients with residual cancer need a maintenance tx plan #LCSM
Brendon Stiles @BrendonStilesMD
@EAustin1969 Without a doubt! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm
Brendon Stiles @BrendonStilesMD
T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-small cell lung cancer. https://t.co/GY6RDUXkmi #lcsm
Dave Bjork @bjork5
#PrecisionMedicine #LCSM
Jean Parks @geekbabe
RT @BrendonStilesMD: T4. Are there any exciting new targets being investigated in lung cancer? #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm
Brendon Stiles @BrendonStilesMD
LIBRETTO! #lcsm https://t.co/at7CJ8sTGf
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm
@shelly_et
Ditto!!! #lcsm
Dave Bjork @bjork5
@BrendonStilesMD What about RET? #LCSM
Jean Parks @geekbabe
RT @BrendonStilesMD: LIBRETTO! #lcsm https://t.co/at7CJ8sTGf
Drew Moghanaki @DrewMoghanaki
Dr. Drew is in finally the house. Just landed in Minneapolis for #AVAHO19 meeting where we are talking about each of these topics as they relate to Veterans with cancer. #lcsm
Brendon Stiles @BrendonStilesMD
T4. RET fusions are only about 2% of NSCLC patients, but great early response to new drug. https://t.co/rkweVlb5bU #lcsm
KC Dill @kasedill
@EAustin1969 This is hope!!! #LCSM
Brendon Stiles @BrendonStilesMD
@bjork5 #lcsm T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-small cell lung cancer. https://t.co/GY6RDUXkmi
KC Dill @kasedill
RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @lcrf_org: @TimAllenMDJD So much work to be done on sorting out the combinations and sequencing of therapy! #lcsm
Henning Willers, MD, FASTRO @HenningWillers
@BrendonStilesMD T4 future may hold biomarker combinations EGFR + Met, KRAS + STK11 et cetera #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: It may play a useful role when assessed along with other molecular biomarkers. Speculation though. #lcsm #CBCIV https://t…
Stephen V Liu, MD @StephenVLiu
T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second line CheckMate studies of nivolumab and 3y follow up from KEYNOTE 024, with first line pembrolizumab (with 3y OS rate of 44%!) #LCSM https://t.co/KhEaOLGhAV
Dave Bjork @bjork5
This!! Support #lungcancer research. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @lgreco_ny @HenningWillers I do think sequencing will come to be important for almost everything in lung cancer! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. RET fusions are only about 2% of NSCLC patients, but great early response to new drug. https://t.co/rkweVlb5bU #…
Brendon Stiles @BrendonStilesMD
T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm
Lung Cancer Research Foundation @lcrf_org
RT @bjork5: This!! Support #lungcancer research. #lcsm https://t.co/gHJ4aUCNv8
#LCSM Chat @lcsmchat
RT @StephenVLiu: T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second lin…
Bob Steele @steele_bob
RT @BrendonStilesMD: T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T4. RET fusions are only about 2% of NSCLC patients, but great early response to new drug. https://t.co/rkweVlb5bU #…
Brendon Stiles @BrendonStilesMD
@HenningWillers I think this is key. We have focused so much on single drivers. Just now starting to understand interplay. #lcsm
#LCSM Chat @lcsmchat
RT @bjork5: This!! Support #lungcancer research. #lcsm https://t.co/gHJ4aUCNv8
Brendon Stiles @BrendonStilesMD
T4. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop https://t.co/EKnlcIWnoT
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Lots of research right now about this. #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: @HenningWillers I think this is key. We have focused so much on single drivers. Just now starting to understand inte…
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: T4. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop https://t.co/EKnlc…
Brendon Stiles @BrendonStilesMD
T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm
Dave Bjork @bjork5
@BrendonStilesMD What about BLU667? Promising? #LCSM #clinicaltrials
Narjust Florez, MD, FASCO @NarjustFlorezMD
@StephenVLiu @IASLC I agree! #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Huge. #lcsm #CBCIV
Brendon Stiles @BrendonStilesMD
T4. As mentioned earlier, moving immunotherapy or targeted therapy into earlier stage disease is also hot. #lcsm
Laura Greco @lgreco_ny
IMO the comment of the plenary was whether we really need Phase III trials against chemo where onc drivers@BrendonStilesMD @bjork5 #lcsm
Jean Parks @geekbabe
@StephenVLiu @IASLC 4 yrs & 4 months on Nivo, stage IV, still working #LCSM
Narjust Florez, MD, FASCO @NarjustFlorezMD
@BrendonStilesMD Together we rise #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @EAustin1969: T3: it’s heartening I see so much progress on treatment options , it’s expanded so much in just 5 years #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm
Brendon Stiles @BrendonStilesMD
T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK, and ROS1. #lcsm
#LCSM Chat @lcsmchat
RT @lgreco_ny: IMO the comment of the plenary was whether we really need Phase III trials against chemo where onc drivers@BrendonStilesMD @…
Brendon Stiles @BrendonStilesMD
@lgreco_ny @bjork5 It is a great question. #lcsm
Pamela Q Fernandes @PamelaQFerns
RT @BrendonStilesMD: T3. Still long way to go for small cell lung cancer. Curves still continue down without plateau. #lcsm https://t.co/…
Jean Parks @geekbabe
RT @BrendonStilesMD: @HenningWillers I think this is key. We have focused so much on single drivers. Just now starting to understand inte…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-s…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK,…
Jean Parks @geekbabe
RT @BrendonStilesMD: T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm
Brendon Stiles @BrendonStilesMD
@NarjustDumaMD You said it right! Thanks for joining! #lcsm
Gina @EAustin1969
@geekbabe @StephenVLiu @IASLC 🎉🎉🎉🎉
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: LIBRETTO! #lcsm https://t.co/at7CJ8sTGf
Jean Parks @geekbabe
RT @BrendonStilesMD: T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK,…
Tim Kruser @TimothyKruserMD
@lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001, showing even more impressive memory sparing with hippocampal avoidance for those pts where whole brain RT is needed. @NRGonc h/t @SeanSachdevMD for the pics! @BrainTumorInst #lcsm https://t.co/zO5UIMKj76
KC Dill @kasedill
@geekbabe @StephenVLiu @IASLC Amazing! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. RET fusions are only about 2% of NSCLC patients, but great early response to new drug. https://t.co/rkweVlb5bU #…
Brendon Stiles @BrendonStilesMD
Here comes T5! #lcsm
Brendon Stiles @BrendonStilesMD
T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Resistance is expected. And highly problematic. Molecular Darwinism. Perhaps to be our greatest cancer molecular therapy challenge. Immunotherapy may ultimately prevail. #lcsm #CBCIV
Jean Parks @geekbabe
RT @TimothyKruserMD: @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001,…
Laura Greco @lgreco_ny
RT @BrendonStilesMD: T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK,…
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Resistance is expected. And highly problematic. Molecular Darwinism. Perhaps to be our greatest cancer molecular therapy…
Janet Freeman-Daily @JFreemanDaily
RT @bjork5: This!! Support #lungcancer research. #lcsm https://t.co/gHJ4aUCNv8
Brendon Stiles @BrendonStilesMD
T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07oQJ5j
@shelly_et
Yes, keep them coming! We need more options. #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
#NoStigma #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Drew Moghanaki @DrewMoghanaki
RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose…
Brendon Stiles @BrendonStilesMD
T5. Special thanks to @KAdvocate_LCAM and to [REDACTED USER] who really made the program happen. And of course to @iaslc #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @bjork5: @BrendonStilesMD What about BLU667? Promising? #LCSM #clinicaltrials
Narjust Florez, MD, FASCO @NarjustFlorezMD
@lcsmchat Late but here! Happy to connect with all. Narjust Duma Thoracic oncologist at @UWCarbone and @uwsmph #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Lung Cancer Research Foundation @lcrf_org
STARS: What an amazing program at this year's #wclc2019 @IASLC #lcsm
Laura Greco @lgreco_ny
Yes! A lot of posters looking at other mechanisms of growth re ALK. #lcsm @HenningWillers @BrendonStilesMD
@dennycee
Sorry to be so late #lcsm
Janet Freeman-Daily @JFreemanDaily
T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advocates (PRAs) & 5 Mentors to #WCLC19 to learn about lung cancer research. Doing it again in 2020 with more PRAs! Learn more here: https://t.co/jHlTI7YGds #LCSM https://t.co/eoqF22fJme
#LCSM Chat @lcsmchat
Also @JFreemanDaily #lcsm
Brendon Stiles @BrendonStilesMD
T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: Susan McCullough, [REDACTED USER], @lgreco_ny, @shelly_et, and [REDACTED USER]. #lcsm https://t.co/hJVVFM9GQW
Centro SOL @jhcentrosol
#communitycentered approach to address depression in the #latinx community. Today we kicked off the patient advisory subcommittee. These community members will inform our work to address #depression. ¿Te gustaría… https://t.co/49AbG4DgPZ
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD I missed readouts from adjuvant trials with targeted therapies--were there any at #WCLC19? #LCSM
Jean Parks @geekbabe
Happy to serve as your human mouse model when needed. Always do blood draws & give extra biopsy samples #lcsm
KC Dill @kasedill
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK,…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
#LikeABoss #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T5. Special thanks to @KAdvocate_LCAM and to [REDACTED USER] who really made the program happen. And of course to @iaslc #lc
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Brendon Stiles @BrendonStilesMD
T5. And they had some incredible mentors: [REDACTED USER], @jillfeldman4, @jFreemanDaily, [REDACTED USER], and @dustywater. Thanks @IASLC. #lcsm https://t.co/m25CoQGRG9
Janet Freeman-Daily @JFreemanDaily
T5. Several patient advocates were invited speakers. Every lung cancer advocate, researcher, clinician, and industry rep should read the #WCLC19 speech delivered by ALK+ NSCLC patient activist and clinical trial Olympian Linnea Olson. #LCSM #clinicaltrials https://t.co/loZAmpfgH3
Laura Greco @lgreco_ny
I can't wait to see what this will be come to be! #stars19 @BrendonStilesMD #lcsm
Jean Parks @geekbabe
RT @NarjustDumaMD: @lcsmchat Late but here! Happy to connect with all. Narjust Duma Thoracic oncologist at @UWCarbone and @uwsmph #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @JFreemanDaily: T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advo…
Drew Moghanaki @DrewMoghanaki
T5: Can someone explain how radiation oncologists can get involved with STARS? #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T5. Several patient advocates were invited speakers. Every lung cancer advocate, researcher, clinician, and industry rep…
Dave Bjork @bjork5
Love this. Thanks @JFreemanDaily 🙌 #LCSM #WCLC19
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @JFreemanDaily: T5. Several patient advocates were invited speakers. Every lung cancer advocate, researcher, clinician, and industry rep…
KC Dill @kasedill
@BrendonStilesMD Loved hearing their updates! #LCSM
Brendon Stiles @BrendonStilesMD
Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and remember why we do what we do when patients are there. #lcsm https://t.co/lAAZQD7Yzz
Road-Astronaut @astronaut_road
Please help me reach my $1k goal. So close! Raising awareness for men’s mental health and prostate cancer by riding in the @gentlemansride dgr_vancouver The link to donate is on the photo above and in my… https://t.co/v2B38c6LZ7
@shelly_et
It is an honor to be involved in this program!! #lcsm
Jean Parks @geekbabe
RT @JFreemanDaily: @BrendonStilesMD I missed readouts from adjuvant trials with targeted therapies--were there any at #WCLC19? #LCSM
Narjust Florez, MD, FASCO @NarjustFlorezMD
@HenningWillers @lcsmchat @BrendonStilesMD Promising but hope we are aware of toxicities... and downstream effects #LCSM
Gina Hollenbeck @GinaHollenbeck
@BrendonStilesMD There was a new assay test for ROS1 developed by Ventana. Relatively cheap and you get the results in 2 days. I wish we could have a comprehensive genomic panel assay;) #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and rememb…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Laura Greco @lgreco_ny
RT @TimothyKruserMD: @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001,…
Brendon Stiles @BrendonStilesMD
@DrewMoghanaki Simply admit that surgery is better than SBRT and you are in... Or if easier, volunteer to help! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. Special thanks to @KAdvocate_LCAM and to [REDACTED USER] who really made the program happen. And of course to @iaslc #lc
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and rememb…
Jill Feldman @jillfeldman4
T5 So sorry...talking one of my college kids off the ledge. Will have to catch up later, but STARS was amazing thanks to [REDACTED USER] @IASLC @JFreemanDaily @KAdvocate_LCAM Can't wait to see how the program expands. We need more educated research advocates #LCSM
Brendon Stiles @BrendonStilesMD
@JFreemanDaily I didn't see any big ones either. None that I am aware of. #lcsm
Drew Moghanaki @DrewMoghanaki
@shelly_et I want to have this honor too! Where can I sign up? #lcsm @jillfeldman4
Brendon Stiles @BrendonStilesMD
Almost time to wind the chat down. This has been an incredible discussion. #lcsm
Drew Moghanaki @DrewMoghanaki
@BrendonStilesMD I will. I will. #FOMO
Dave Bjork @bjork5
I agree #LCSM @J2Novack @1111linno 🙌
Sue McCullough @SueMcCu30398663
Sue Mc, I am here, just watching 💚#LCSM
Brendon Stiles @BrendonStilesMD
Please share your closing thoughts! #lcsm
Brendon Stiles @BrendonStilesMD
Thanks to all of the #lcsm community who joined. And BIG thanks to @IASLC for all they do for lung cancer. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S…
Brendon Stiles @BrendonStilesMD
@SueMcCu30398663 Hi Sue! #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Thank you, @BrendonStilesMD, for hosting this great #lcsm session. It was a privilege to participate.
Laura Greco @lgreco_ny
Are you ever home? #lcsm
Brendon Stiles @BrendonStilesMD
#WCLC19 was an incredible meeting. Great to get so many people together from so many different specialties. #lcsm https://t.co/kjR3NAeD7x
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Please share your closing thoughts! #lcsm
Lung Cancer Research Foundation @lcrf_org
Great discussion on tonight's #lcsm chat. Thank you @BrendonStilesMD and @JFreemanDaily!
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @lcrf_org: Great discussion on tonight's #lcsm chat. Thank you @BrendonStilesMD and @JFreemanDaily!
IASLC @IASLC
The registration deadline for the IASLC 2019 North America Conference on Lung Cancer has been extended to September 25! Register now to learn about the latest developments in #LungCancer prevention, detection and care at #NACLC19 --> https://t.co/1b4iyU3MSw #LCSM https://t.co/HsSRzyXSkO
Gina Hollenbeck @GinaHollenbeck
@BrendonStilesMD The Stars program is an awesome and important addition to #WCLC. It’s a wonderful idea. I look forward to seeing how the stars use the information learned in Barcelona #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and rememb…
Bob Steele @steele_bob
RT @lcrf_org: Great discussion on tonight's #lcsm chat. Thank you @BrendonStilesMD and @JFreemanDaily!
yetAnotherName @glostaMAssachu
Tomorrow marks the 21st anniversary of my Mom’s death from lung cancer. Treatment options and current research now weren’t even dreams then! Imagine where we’ll be in another 21 years! ❤️ #lcsm
Janet Freeman-Daily @JFreemanDaily
@DrewMoghanaki Talk to me or @KAdvocate_LCAM! #LCSM
Brendon Stiles @BrendonStilesMD
Always a closing thought for me.... #Research moves the needle and has made all the difference in lung cancer. Let's support it as a community! #lcsm
#LCSM Chat @lcsmchat
Thanks to our moderator @BrendonStilesMD for tonight’s chat! #LCSM
Tim Kruser @TimothyKruserMD
Final thought relates to T5. STARS progam--amazing. We need to get some of these superstars at #ASTRO20. Can you say Miami?! #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: #WCLC19 was an incredible meeting. Great to get so many people together from so many different specialties. #lcsm htt…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: Always a closing thought for me.... #Research moves the needle and has made all the difference in lung cancer. Let's s…
#LCSM Chat @lcsmchat
RT @IASLC: The registration deadline for the IASLC 2019 North America Conference on Lung Cancer has been extended to September 25! Register…
Gina @EAustin1969
The advances in both early detection and treatment options and spans is so amazing. We definitely have to badger, bother and pester to get more funding for more research so that many can live with this disease and not die #lcsm
Brendon Stiles @BrendonStilesMD
@JFreemanDaily @DrewMoghanaki @KAdvocate_LCAM I would watch this guy carefully... #lcsm
#LCSM Chat @lcsmchat
RT @GinaHollenbeck: @BrendonStilesMD The Stars program is an awesome and important addition to #WCLC. It’s a wonderful idea. I look forward…
#LCSM Chat @lcsmchat
RT @wildwestannie: Tomorrow marks the 21st anniversary of my Mom’s death from lung cancer. Treatment options and current research now were…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and rememb…
Lung Cancer Research Foundation @lcrf_org
The pace of innovation in lung cancer continues to accelerate thanks to the dedication of so many people! #lcsm
Brendon Stiles @BrendonStilesMD
@TimothyKruserMD Great point! #lcsm
#LCSM Chat @lcsmchat
RT @TimothyKruserMD: Final thought relates to T5. STARS progam--amazing. We need to get some of these superstars at #ASTRO20. Can you say M…
KC Dill @kasedill
@BrendonStilesMD As always thanks for the moderation and information. Lots of exciting news and hope from the conference. I look forward to our monthly chats. #LCSM #ResearchMatters
#LCSM Chat @lcsmchat
RT @EAustin1969: The advances in both early detection and treatment options and spans is so amazing. We definitely have to badger, bother…
Brendon Stiles @BrendonStilesMD
Thanks to everyone for participating! #lcsm
#LCSM Chat @lcsmchat
RT @lcrf_org: The pace of innovation in lung cancer continues to accelerate thanks to the dedication of so many people! #lcsm
Dave Bjork @bjork5
Thank you @IASLC and all the amazing lung cancer patient advocates who travel near and far for our community. And @BrendonStilesMD for hosting tonight. ❤️ #lcsm #community #gratitude
Henning Willers, MD, FASTRO @HenningWillers
Glad to have attended this chat. As always. Thanks & see you at #NACLC19 #LCSM
Drew Moghanaki @DrewMoghanaki
@BrendonStilesMD @JFreemanDaily @KAdvocate_LCAM Thanks Janet. #lcsm
Laura Greco @lgreco_ny
@HenningWillers @BrendonStilesMD @lcrf_org Anything else re treatment of oligoprogressive disease? #lcsm
Brendon Stiles @BrendonStilesMD
@lcrf_org Great point. And the rapid pace is hard to keep up with. Thanks #lcsm and @lcsmchat for helping to keep patients, advocates, physicians, and researchers abreast. #lcsm
Drew Moghanaki @DrewMoghanaki
@BrendonStilesMD I will. I will. #FOMO #lcsm @jillfeldman4
Brendon Stiles @BrendonStilesMD
@HenningWillers Awesome! I will be there and am counting on meeting you! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to @IASLC for all they do for lung cancer. #lcsm
Bob Steele @steele_bob
Time to start reviewing all of the INFO links from tonight's excellent monthly Lung Cancer Social Media Twitter Chat Session. Cheers! #lcsm
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: #WCLC19 was an incredible meeting. Great to get so many people together from so many different specialties. #lcsm htt…
Dave Bjork @bjork5
#RockStar #lcsm @BrendonStilesMD #research
Brendon Stiles @BrendonStilesMD
How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Henning Willers, MD, FASTRO @HenningWillers
@BrendonStilesMD I will be standing by my poster 😇 #lcsm
Drew Moghanaki @DrewMoghanaki
RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD Thanks @BrendonStilesMD and all participating docs and patients for a great wrap-up of @IASLC #WCLC19. It gets better every year! Looking forward to next year in #Singapore ! #LCSM
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Brendon Stiles @BrendonStilesMD
Thanks everyone. Love the community and love learning from all of you! Signing off but hope to see or hear from everyone soon. #lcsm
Jenni Chrysler @jenchrysler98
RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Tim Kruser @TimothyKruserMD
RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Jean Parks @geekbabe
Thanks to all the Oncologists, researchers & pt advocates & our gracious host! #LCSM
KC Dill @kasedill
Thank you @IASLC for the research, hope and community!! #LCSM #ResearchMatters #EvidenceBasedMedicine
Bob Steele @steele_bob
Good night all! Look forward to seeing you next month. #lcsm
Dave Bjork @bjork5
@JFreemanDaily @BrendonStilesMD @IASLC Thanks for being relentless. 🙌😊 #lcsm #research
Laura Greco @lgreco_ny
@TimothyKruserMD Si! Get us funding to get there! #lcsm
Dr. Amy C. Moore @acmoorephd
It was an honor to partner with patient groups and our advocacy friends to disrupt the research paradigm at #WCLC19 #lcsm https://t.co/aFFvJZ9HUC
Jean Parks @geekbabe
@kasedill @StephenVLiu @IASLC I have a great Oncologist at @MGHCancerCenter #LCSM
Laura Greco @lgreco_ny
RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Henning Willers, MD, FASTRO @HenningWillers
@lgreco_ny @BrendonStilesMD @lcrf_org #ASTRO was allow about oligometastatic disease. Lots of promise to use #SABR , little data still. Nice study from @YaleCancer showing 10% systemic response rate with radiation #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Laura Greco @lgreco_ny
RT @JFreemanDaily: T5. Several patient advocates were invited speakers. Every lung cancer advocate, researcher, clinician, and industry rep…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Thanks everyone. Love the community and love learning from all of you! Signing off but hope to see or hear from every…
Laura Greco @lgreco_ny
@BrendonStilesMD What the heck am I doing?
Lung Cancer Sux @LungCancerSux
Great book for clinicians as well as patients and their families! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @acmoorephd: It was an honor to partner with patient groups and our advocacy friends to disrupt the research paradigm at #WCLC19 #lcsm h…
Dr. Amy C. Moore @acmoorephd
@BGitlitz_MD and I shared final results from ALCMI’s “Genomics of Young Lung Cancer” study which found that over 80% of patients under age 40 have targetable mutations #WCLC19 #lcsm https://t.co/2p5JBplT5y
Dr. Amy C. Moore @acmoorephd
My colleague Andrew Ciupek shared data from the Lung Cancer Registry on patient experiences #lcsm #WCLC19 https://t.co/HIv8Gr2kQD
Matthew Katz, MD 🇺🇸🟦 @subatomicdoc
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Devika Das, MD, MSHQS @DevikaDasMD
@NarjustDumaMD @BrendonStilesMD @lcsmchat @IASLC Will have to read the #lcsm chat transcript from today -could not multitask from #AVAHO19 😢
Dr. Amy C. Moore @acmoorephd
Was honored to share the story of my road to research advocacy with the @IASLC #STARS participants in Barcelona. They always inspire and teach me. #WCLC19 #lcsm https://t.co/w8TazpFnjT
Janet Freeman-Daily @JFreemanDaily
Transcript for tonight's #LCSM Chat "World Lung (#WCLC19) Wrap-Up" is here: https://t.co/FbqsKqsX2r
Sue McCullough @SueMcCu30398663
@shelly_et Shelly you are right It is really an honor to be apart of this STARS group. Sue Mc #LCSM
KC Dill @kasedill
@StephenVLiu @IASLC I like to think of myself as a dot on that graph! #LCSM #ResearchMatters #EvidenceBasedMedicine
Lecia Sequist, MD, MPH @LeciaSequist
@BrendonStilesMD I really enjoy the multidisciplinary nature of WCLC. It’s fantastic! #LCSM
KC Dill @kasedill
Excellent Chat! Thanks @JFreemanDaily #LCSM
#LCSM content from Twitter.